Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 4, pp 740–743 | Cite as

The role and strategy of ISoP in global pharmacovigilance

  • Sten OlssonEmail author
  • Mira Harrison-Woolrych
Commentary

Abstract

Applying the WHO definition of pharmacovigilance, the International Society of Pharmacovigilance, (ISoP) is concerned with all aspects of medicine safety. The safety of patients exposed to medicines depends on a wide variety of factors, where the understanding of each factor is associated with its own professional competence and skillset. For pharmacovigilance systems to work efficiently, a broad understanding of the necessary contribution of each of the different scientific competence areas and professional skills is required. ISoP is an independent, not-for-profit international professional organization, concerned with the best interest of patients exposed to pharmaceutical interventions in all healthcare systems in the world. ISoP offers an open platform for professionals from around the world with different expertise and skillsets, to network and exchange information and knowledge in a friendly environment. The society wishes to become a stronger global voice, speaking up in favour of patient safety and to be at the frontline of the global patient safety movement.

Keywords

Drug safety International association Non-profit Patient safety Pharmacovigilance 

Notes

Funding

None.

Conflicts of interest

The authors declared that they have no conflict of interest.

References

  1. 1.
    Moore N, Biour M, Paux G, Loupi E, Begaud B, Boismare F, et al. Adverse drug reaction monitoring: doing it the french way. Lancet. 1985;2(8463):1056–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Anonymous. The importance of Pharmacovigilance. Safety monitoring of medicinal products WHO 2002 http://apps.who.int/iris/bitstream/10665/42493/1/a75646.pdf. Accessed 11 Jan 2018.
  3. 3.
    www.isoponline.org. Accessed 11 Jan 2018.
  4. 4.
    Velo G. Ecopharmacovigilance. In: Edwards IR, Lindquist M, editors. Pharmacovigilance, critique and ways forward. Berlin: Springer; 2017. p. 195–205.Google Scholar
  5. 5.
    Olsson S, Wong ICK, Delumeau J-C, Harrison-Woolrych M. The new phase of ISoP. Drug Saf. 2017;40:841–4.CrossRefPubMedGoogle Scholar
  6. 6.
    The International Society of Pharmacovigilance 18th Annual Meeting. http://www.isop2018geneva.org/. Accessed 18 July 2018.
  7. 7.
    McCarthy D, Bahri P, Barnres J, Delumeau J-C, Edwards B, Harrison-Woolrych M. An update on ISoP special interest groups (SIGs). Drug Saf. 2018;41:1–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, Hartigan-Go K, Hugman B, Mol PG. The ISoP CommSIG for improving medicinal product risk communication: a new special interest group of the International Society of Pharmacovigilance. Drug Saf. 2015;38:621–7 (on behalf of the ISoP CommSIG).CrossRefPubMedGoogle Scholar
  9. 9.
    Anonymous. WHO pharmaceuticals newsletter no 6, 2017, p. 22 http://www.who.int/medicines/publications/PharmaNewsletter6_17/en/. Accessed 11 Jan 2018.
  10. 10.
    Beckmann J, Hagemann U, Bahri P, Bate A, Boyd IW, Dal Pan GJ, et al. Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. Drug Saf. 2014;37:743–59.CrossRefPubMedGoogle Scholar
  11. 11.
    Springer-Nature. Drug safety journal. https://www.springer.com/adis/journal/40264. Accessed 18 July 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.The International Society of PharmacovigilanceLondonUK

Personalised recommendations